EMA's Committee for Advanced Therapies ("CAT") is organizing a workshop on November 15 and 16, 2016, to discuss scientific and regulatory challenges of immunotherapy medicines based on genetically modified T-cells (white blood cells that normally fight off viruses and bacteria). The open workshop aims to facilitate dialogue between the CAT and medicine developers from industry and academia on:
- Â Current scientific developments;
- Regulatory requirements for product manufacture and testing; and
- Non-clinical studies and clinical development.
The workshop program is available online, and the event will be broadcast live. People interested in participating are invited to register using the form available on the website.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.